Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Histologically or cytologically documented B-cell non-Hodgkin's lymphoma, including any of the following histologic types: * Follicular large B-cell lymphoma (follicular, grade 3) * Follicular mixed cell lymphoma (follicular, grade 2) * Diffuse mixed cell lymphoma * Diffuse large B-cell lymphoma * Immunoblastic lymphoma * Burkitt or Burkitt-like lymphoma * Anaplastic large cell lymphoma * Primary effusion lymphoma * All stages eligible * Seropositive for HIV by any approved test or positive HIV-1 RNA in plasma at anytime in the past * Prior documentation of HIV seropositivity allowed * Received 1 prior anthracycline-based regimen of curative intent * No more than 1 prior regimen * Measurable or evaluable disease * Evaluable disease defined as not having bidimensional measurements (i.e., gastric or marrow involvement) but can be followed for response by other diagnostic tests, such as gallium scan, positron emission tomography (PET) imaging and/or bone marrow biopsy * No primary CNS lymphoma * Lymphomatous meningitis or brain metastasis eligible provided other measurable systemic lymphomatous disease is also present * Less than 25% bone marrow involvement with lymphoma * Concurrent effective highly active anti-retroviral therapy (HAART) required at study entry * HIV viral load \< 100,000 copies/mL if HAART was not used previously PATIENT CHARACTERISTICS: * Karnofsky performance status 50-100% * Bilirubin ≤ 2.0 mg/dL (unless elevated due to lymphom…